Investor Presentaiton

DNA Q4 2018 - Strong mobile device sales in the last quarter Growth of mobile service revenue (+4.6%) and strong mobile device sales (+7.3%) boosted quarters' net sales EUR million y-on-y+1.2% in Q4/2018 235 213 219 219 222 222 225 225 228 228 237 237 EBITDA¹ declined 4.5% from the reference period and margin was +26.4% EUR million y-on-y -4.5% in Q4/2018 73 72 71 72 73 66 68 66 76 76 33.5% 63 65 33.2% 32.5% 32.0% 30.9% 30.8% 28.0% 27.6% 31.8% 32.3% 33.5% 26.4% Q1/2017 Q2/2017 Q3/2017 Q4/2017 Q1/2018 Q2/2018 Q3/2018 Q4/2018 Q1/2017 Net sales Net sales (IFRS 15) Q2/2017 Q3/2017 Q4/2017 Comparable EBITDA as a % of Revenue Comparable EBITDA Q1/2018 Q2/2018 Q3/2018 Comparable EBITDA (IFRS 15) Q4/2018 Operative capex² decreased year-on-year, investments were distributed more evenly in 2018 Operative free cash flow³ increased from the reference period EUR million y-on-y-20.1% in Q4/2018 EUR million 49 67 28.7% 24 24 17 11.1% 11.2% 7.9% Q1/2017 Q2/2017 Q3/2017 48 54 54 31 31 16 15 13.7% 7.1% 7.0% 34 34 22.7% 14.9% 22.7% 13.6% 15.0% Q4/2017 Q1/2018 Q2/2018 Q3/2018 Q4/2018 23.0% 43 19.7% 22.0% 56 55 25.4% 41 42 42 42 18.3% 18.6% 24.8% 18.7% -0.7% 18.6% 9 12 3.7% 4.9% Q1/2017 Q2/2017 -2 Q3/2017 Q4/2017 Q1/2018 Q2/2018 Q3/2018 Q4/2018 Operative Capex as a % of Revenue Operative Capex DNA's Investor presentation, February 2019 Operative Capex (IFRS 15) Operating Free Cash Flow (IFRS 15) Notes Operating FCF as a % of Revenue Operating Free Cash Flow 1. EBITDA excluding items affecting comparability 2. Operative capex excluding spectrum license payments 3. Operating free cash flow defined as comparable EBITDA minus operative capex 17

View entire presentation